Please login to the form below

Not currently logged in
Email:
Password:

Dexcom and Fitbit team up to tackle diabetes management

Will develop a wearable blood glucose tracking product

Fitbit

Continuous glucose monitoring (CGM) specialists DexCom and wearable brand company Fitbit will team up to develop a new blood glucose tracking product for people with diabetes.

The initiative will bring together Dexcom’s CGM data and Fitbit’s new Ionic smart watch - which is compatible with both iOS and Android devices - to monitor activity and glucose levels from the users wrist.

James Park, chief executive officer, Fitbit, said: “Our ability to track critical health metrics coupled with Dexcom’s market leadership in CGM present a powerful combination that we hope will help millions of people better manager their diabetes.”

According to the World Health Organization, more than 400 million people across the globe are estimated to be living with diabetes.

Park added: “With Ionic, we are focused on driving positive health outcomes and more health focused tools, and this collaboration is a wonderful example of how we plan to bring that vision to our users.”

The deal isn’t Fitbit’s first life sciences partnership, and the Dexcom deal follows last year’s tie-up with medical device group Medtronic to integrate its CGM mobile app with the company’s wearable.

The future Fitbit-Dexcom device will come armed with a sensor to track a user’s heart rate and detect blood oxygen levels.

Along with the Fitbit’s original capabilities, the Ionic will also feature GPS-tracking and on-device workouts, as well as smart features such as contactless payment, music, and notifications.

Kevin Sayer, president and chief executive officer, Dexcom, said: “The collaboration between Dexcom and Fitbit is an important step in providing useful information to people with diabetes that is both convenient and discreet.

Sayer added: “We believe that providing Dexcom CGM data on Fitbit Ionic, and making the experience available to users to both Android and iOS devices, will have a positive impact on the way people manage their diabetes.”

The companies are set to drive out the product “as soon as possible” in 2018.

Article by
Gemma Jones

2nd November 2017

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics